Being a modulator of the N-methyl-D-aspartate (NMDA) receptor function magnesium has been studied for its neuroprotective and vasodilatative properties in acute and delayed brain ischemia due to vasospasm in aneurysmal subarachnoid haemorrhage (aSAH) and stroke. A number of clinical phase II and III studies have correlated serum magnesium concentrations after intravenous continuous application to clinical outcome and have failed to show a positive therapeutic effect. However, no study supported its conclusion by providing evidence for a local increase in magnesium, i.e. in the cerebrospinal fluid (CSF) and the brain parenchyma. The objective of our observational study was to compare magnesium levels in serum, CSF, and brain microdialysis samples (MDS) in patients with aSAH. Seventeen patients with aSAH at World Federation of Neurosurgeons (WFNS) grade IV and V were included. According to our internal standard treatment protocols, all patients received a ventricular catheter, a frontal intracerebral microdialysis probe, and a continuous intravenous application of 80 mmol MgSO4 per 24 hours. Magnesium concentrations of serum, CSF, and MDS were recorded. We found a positive and significant correlation of increased serum levels of magnesium to CSF and MDS magnesium concentrations. These pharmacokinetic findings may serve as a basis for further discussion of the concept of induced hypermagnesemia in patients with aSAH, especially in the context of recent level A evidence of the lack of clinical benefit.
Introduction
Interest in magnesium as a neuroprotectant and antivasospastic agent for the therapy in cerebral aneurysmal subarachnoid haemorrhage (aSAH) and stroke, but also in perinatal hypoxia, has risen over the last couple of years, but declined after publication of a phase III international multicenter placebo controlled trial (MASH-2) [1] and a meta-analysis [2] in 2012, both concluding that prophylactic intravenous magnesium does not improve neurological outcome in patients with aSAH. Since the first description of reversal of delayed cerebral vasospasm by magnesium in rats [3] and a pilot study on the management of patients with a Fisher Grade 3 aSAH [4] , numerous case studies [5] and larger dose finding clinical study [6] were published, partially with good and promising clinical outcomes [7] . An animal study on transient focal cerebral ischemia in rats concluded that a serum magnesium level between 2.0 and 3.0 mmol/L offered best protection [8] . None of the aforementioned studies, however, correlated the dependent variable (e.g. clinical outcome, Doppler ultrasound examinations, neuroradiological or neuropathological studies) with the level of magnesium in either cerebrospinal fluid (CSF) or brain parenchyma but only to serum levels.
The rational of magnesium application for the treatment of cerebral vasospasm and stroke is mainly based upon the voltage-dependent blockage of the N-methyl-D-aspartate (NMDA) receptor [9] which effects cellular energy metabolism, vascular tone, and cell membrane transport [10] . Magnesium causes vasodilatation by stimulation of endothelial prostacyclin release and prevents vasoconstriction by a variety of mediators [11] .
The aim of our study was to investigate the correlation of magnesium concentration in serum Due to the limitations of the study we did not match clinical outcome or vasospasm scores with magnesium measurements.
Microdialysis and Measurements
Microdialysis was performed using a catheter with a membrane length of 10 mm and a cut-off at 20.000 Dalton (CMA 70, CMA Microdialysis AB, Solna, Sweden). The pump rate was 0.3 μl/min of Mg 2+ free perfusion fluid (perfusion fluid T1, CMA Microdialysis AB). Serum and CSF was collected once a day, microdialysis specimens were collected twelve times a day (every two hours) and pooled daily after analysis for standard parameter to yield sufficient dialysate for Mg 2+ analysis. The daily analysis of CSF, serum, and microdialysis specimens for magnesium concentration was done in the hospital laboratory using a standard colorimetric endpoint method with xylidil blue.
Statistics
The raw data were adjusted using the ICU pilot software (CMA Microdialysis AB), the mean and standard deviation was calculated using Windows Excel and GraphPad Prism 2.0.
Results

Patients with Magnesium Application
We identified 17 (6 male/11 female) consecutive patients with a WFNS grade IV (8 patients) and V (9 patients) aSAH who received a standard ventricular drain, a frontal implantation of a microdialysis probe, and an intravenous continuous magnesium application. However, not all initially planned samples could be collected from every patient due to technical reasons (e.g. failure of the microdialysis pump, clotted external drain). The daily average number of collected specimens from day 0 to day 8 were 8.1 MDS specimens (range: 6 to 11 specimens), 9.0 CSF specimens (4 -12), and 11.8 serum specimens (8 -14) . In none of the patients magnesium application had to be adjusted to comply with the maximum serum level of 3.0 mmol/L.
At three months, of all patients under observation 13 patients reached a Glasgow outcome scale (GOS) below or equal 3, two patients had a GOS of 4, and two patients had a full recovery (GOS 5).
We did not observe any cardiotoxic effects or unexplained cardiopulmonary events due to application of magnesium during or after the observation period, although magnesium application was carried on for as long as 26 days in selected patients at the dosages specified above.
Patients without Magnesium Application
Furthermore we identified 15 comatose patients with diagnoses other than aSAH who also had a microdialysis bold catheter (six patients with spontaneous intracerebral haemorrhages, seven patients with head trauma, and two patients with malignant brain ischemia). Typically, these patients did not have an external ventricular drainage and were not given magnesium. The daily average number of collected specimens from day 0 to day 8 was 7.6 MDS specimens (range: 1 to 16 specimens) and 7.8 serum specimens (1 -15).
Magnesium Measurements
We observed an increase of [ ] MDS slowly increased to 0.63 mmol/L at day 7, therefore corresponding to a 1.53-fold increase of the initial measurement. The unpaired t-test comparing day 0 to day 7 is significant for all three parameters (Figure 1) In patients with diagnoses other than aSAH and without intravenous application of magnesium (Figure 2) 
Discussion
We were able to show that a continuous intravenous application of magnesium sulphate does result in an in this increase did not result in a measurable increase of [Mg 2+ ] MDS . In neurovascular diseases, extracellular magnesium has only been measured in animals by means of cerebral microdialysis. Magnesium administration has been shown to result in an increase of extracellular magnesium in miniswine [14] . It was shown in gerbils [15] that after cerebral ischemia and reperfusion, the level of magnesium dropped to 41% and gradually returned to 67% of baseline measurements, using an on-line automated microdialysis spectrometry for the measurements. The authors concluded that derangement of magnesium homeostasis could be important in brain cell injury. It was also shown that magnesium supplementation in gerbils may be beneficial in providing an additional glucose source and may also improve the recovery of energy substrates in the brain during and after forced exercise [16] . In earlier studies from the same group, common extracellular metabolites were measured in gerbils subjected to focal ischemia after pretreatment with magnesium [17] . Post-ischemic decreases of extracellular glucose and pyruvate were not as pronounced in the magnesium group compared to the control group. In our series, a similar decline of [Mg 2+ ] MDS was not found in patients with cerebral pathologies other than aSAH (Figure 2) .
In trauma, however, there had been one report on magnesium microdialysis measurements in 43 patients, showing that the concentration of magnesium did not correlate to the extent of physiological deterioration [18] . Again, in the small and unselected group of seven trauma patients within our series, [ ] ecf are expected to be beneficial [14] . Further studies of extra-and intracellular distribution of magnesium in patients with SAH and continuous intravenous magnesium therapy are of interest, but difficult to perform.
A recent study on the brain bioavailability of intravenously administered magnesium in patients with acute brain injury concluded that induced hypermagnesemia of 2.1 to 2.5 mmol/l only marginally increased [Mg 2+ ] CSF [20] . Intravenous magnesium application was carried out for 24 hours and [Mg 2+ ] CSF was determined at baseline, twelve, 24, and 36 hours. The maximum increase was found to be 15%. This corresponds to our data.
The issue of limited intracerebral availability of magnesium was also discussed by the authors of MASH-2 [1] as a possible explanation for magnesium not improving outcome after aSAH. Therefore, these pharmacokinetic findings presented here are important and may serve as a basis for discussion of future preclinical and clinical investigations carried out to identify the therapeutic role of intravenous magnesium application in preventing acute or delayed brain ischemia in SAH and stroke.
As a relevant limitation of this study, and as mentioned before, the authors would like to underline that for some patients, it was not possible to collect daily samples due to technical reasons, such as clotted external drains. This could possibly lead to a collection bias and a misinterpretation of the results.
Continuous This pharmacokinetic association has not been shown before and underlines one of the therapeutic principles in induced hypermagnesemia in aSAH. Hence, these findings add to the discussion of neuroprotective and antivasospastic therapy in the context of recently failed magnesium trials.
